Jin Seok Ahn

Research interests

Publications

• Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2310532

• Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.04.478

• Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-16164-1

• DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

  Nature Communications · 2019 · https://doi.org/10.1038/s41467-019-12159-9

• Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30504-2

• Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1704795

• Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw559

• Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.63.9443

• The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma

  Blood · 2007 · https://doi.org/10.1182/blood-2007-01-067769

Current projects

No projects listed.